| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8453639 | Lung Cancer | 2018 | 18 Pages |
Abstract
This case further illustrates the importance of comprehensive genomic profiling of resistant tumors for tailoring treatment decisions after disease progression on crizotinib in ALKâ¯+â¯NSCLC in the era of rapidly developing new-generation ALK inhibitors and other therapeutic strategies.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Xinghao Ai, Xiaomin Niu, Lianpeng Chang, Rongrong Chen, Sai-Hong Ignatius Ou, Shun Lu,